-
CACA GU丨Yiping Zhu: Advancing Standardized, Whole-Course Bladder Cancer Management—from First-Line Treatment Innovation to Multidisciplinary Collaboration
The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. In recent years, the rapid development of antibody-drug conjugates (ADCs) and immunotherapy has reshaped the first-line treatment landscape for locally advanced or metastatic urothelial carcinoma (LA/mUC), while closer coordination among systemic therapy, surgery, and long-term follow-up has become increasingly important. Although emerging evidence has…
-
2026 Pujiang Urological Oncology Academic Conference丨Yijun Shen: ADCs Are Driving Bladder-Preservation Strategies Toward Precision Combination Therapy—from Combination Treatment in High-Risk NMIBC and MIBC Pathway Reshaping to Molecular Biomarker Stratification
The rapid development of antibody-drug conjugates (ADCs) and immunotherapy is driving bladder-preservation strategies beyond single-modality local treatment toward an integrated approach combining systemic therapy, local treatment, and molecular stratification. Oncology Frontier – UroStream invited Professor Yijun Shen of Fudan University Shanghai Cancer Center to discuss combination bladder-preservation strategies for high-risk non-muscle-invasive bladder cancer (NMIBC), the…
-
2026 Pujiang Urological Oncology Academic Conference丨Professor Guohai Shi: From Combination Therapy to Whole-Course Management, Advancing Long-Term Benefit in Advanced Renal Cell Carcinoma
The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. With the deeper integration of targeted therapy and immunotherapy, survival outcomes for advanced renal cell carcinoma (RCC) continue to improve. Clinical attention has also shifted from “whether to combine treatments” toward “how to select the optimal combination, how to sequence subsequent therapies, and how…
-
CACA GU丨Professor Xin Yao: Advancing Full-Course Urological Cancer Management Through Precision, Refinement, and Continuous Excellence
The diagnosis and treatment of urological cancers are currently undergoing a period of rapid evolution, driven by simultaneous advances in drug innovation and surgical techniques. Treatment strategies for urothelial carcinoma in the first-line and perioperative settings are evolving rapidly, while surgery for complex renal tumors is shifting from a focus on short-term safety toward greater…
-
Joe M. O’Sullivan Professor: APCCC 2026 Updates and Insights — Controversies in Hormonal Therapy Sequencing and Combination Strategies, the Prospects of Radioligand Therapy, and Global Equity in Prostate Cancer Care
In 2026, the Advanced Prostate Cancer Consensus Conference (APCCC), one of the most influential international expert consensus meetings in advanced prostate cancer, brought together experts from around the world to discuss systemic treatment strategies, risk-adapted treatment decisions, and emerging combination therapies, providing important guidance for clinical practice worldwide.
-
2026 Pujiang Urological Oncology Academic Conference丨Professor Hailiang Zhang: From Mechanisms of Immunotherapy Resistance to Precision Risk Stratification and Treatment—New Insights from the “Eggshell Structure” Discovered Through Spatial Multi-Omics and Advances in Systemic Therapy for Urological Tumors
Systemic therapy for urological tumors is undergoing a profound transformation, shifting from empiric treatment toward mechanism-driven, precision-based risk stratification and whole-course management. In clear cell renal cell carcinoma (ccRCC), the immune-excluded tumor microenvironment is an important factor influencing the efficacy of immune checkpoint inhibitors. In urothelial carcinoma, antibody-drug conjugates (ADCs) combined with immunotherapy are moving…
-
CACA GU丨Professor Gang Zhu: Integrating the Full-Course Management of Urological Cancers—from Strengthening Prevention and Screening to Multidisciplinary Collaboration
The 2026 Annual Meeting of the Chinese Anti-Cancer Association (CACA) Urological Oncology Committee was held in Tianjin. The meeting brought together experts to discuss standardized diagnosis and treatment of urological cancers, multidisciplinary collaboration, and full-course cancer management. As diagnostic and therapeutic technologies continue to advance, how to truly integrate prevention, screening, diagnosis, treatment, and rehabilitation,…
-
CACA GU丨Yuanxin Jia: Advancing Comprehensive Urologic Oncology Management Through Precision, Risk Stratification, and Individualized Care
With the accelerating aging of the population, health screening has been increasingly promoted across medical institutions at different levels. As a result, the early detection rates of urologic malignancies, including prostate, bladder, and kidney cancers, have improved, while standardized disease management has received growing attention. Against this backdrop, important challenges in clinical practice include how…
Connecting Medical Expertise through Media